M A Rosenthal

Summary

Affiliation: Ludwig Institute for Cancer Research
Country: Australia

Publications

  1. ncbi request reprint Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme
    M A Rosenthal
    Department of Clinical Haematology and Medical Ontcology, Royal Melbourne Hospital, Victoria, Australia
    J Neurooncol 47:59-63. 2000
  2. ncbi request reprint Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin
    M A Rosenthal
    Centre for Developmental Cancer Therapeutics, Parkville, Australia
    J Clin Oncol 19:519-24. 2001
  3. ncbi request reprint Small cell lung cancer with tracheal obstruction
    B H C Le
    Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria, Australia
    Intern Med J 35:490. 2005
  4. ncbi request reprint Five years managing metastatic non-small cell lung cancer: experience at a teaching hospital
    S Wong
    Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
    Intern Med J 34:458-63. 2004
  5. ncbi request reprint An Australian experience with temozolomide for the treatment of recurrent high grade gliomas
    M T Harris
    Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia
    J Clin Neurosci 8:325-7. 2001
  6. ncbi request reprint Temozolomide-induced flare in high-grade gliomas: a new clinical entity
    M A Rosenthal
    Department of Medical Oncology and Clinical Haematology, Royal Melbourne Hospital, Parkville, Victoria, Australia
    Intern Med J 32:346-8. 2002
  7. ncbi request reprint Staged autologous peripheral blood progenitor cell transplantation for Ewing sarcoma and rhabdomyosarcoma
    D S Ritchie
    Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
    Intern Med J 34:431-4. 2004
  8. doi request reprint Survival comparison between glioblastoma multiforme and other incurable cancers
    B Tran
    Department of Medical Oncology, Royal Melbourne Hospital, Grattan Street, Parkville, Victoria 3050, Australia
    J Clin Neurosci 17:417-21. 2010
  9. doi request reprint Imaging modalities in high-grade gliomas: pseudoprogression, recurrence, or necrosis?
    I Caroline
    Department of Medical Oncology, Royal Melbourne Hospital, Grattan Street, Parkville, Victoria 3050, Australia
    J Clin Neurosci 19:633-7. 2012
  10. ncbi request reprint Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia
    M A Rosenthal
    Department of Medical Oncology and Clinical Hematology, Royal Melbourne Hospital, Parkville, Victoria, Australia
    Ann Oncol 13:770-6. 2002

Detail Information

Publications14

  1. ncbi request reprint Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme
    M A Rosenthal
    Department of Clinical Haematology and Medical Ontcology, Royal Melbourne Hospital, Victoria, Australia
    J Neurooncol 47:59-63. 2000
    ..The median overall survival was 12 weeks (range 3-60+ weeks). In conclusion, the combination of Taxol and EMP is well tolerated and has modest activity in the treatment of recurrent GBM...
  2. ncbi request reprint Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin
    M A Rosenthal
    Centre for Developmental Cancer Therapeutics, Parkville, Australia
    J Clin Oncol 19:519-24. 2001
    ..To determine the recommended dose, toxicity profile, and pharmacokinetics of a novel boronated porphyrin (BOPP) for photodynamic therapy (PDT) of intracranial tumors...
  3. ncbi request reprint Small cell lung cancer with tracheal obstruction
    B H C Le
    Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria, Australia
    Intern Med J 35:490. 2005
  4. ncbi request reprint Five years managing metastatic non-small cell lung cancer: experience at a teaching hospital
    S Wong
    Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
    Intern Med J 34:458-63. 2004
    ..The management of patients with metastatic non-small cell lung cancer (NSCLC) is complex. Some studies have demonstrated that the care of patients with NSCLC may be suboptimal...
  5. ncbi request reprint An Australian experience with temozolomide for the treatment of recurrent high grade gliomas
    M T Harris
    Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia
    J Clin Neurosci 8:325-7. 2001
    ..There were no episodes of febrile neutropenia and temozolomide was generally well tolerated. In conclusion, temozolomide is an active therapy in patients with recurrent high grade glioma and our results concord with published studies...
  6. ncbi request reprint Temozolomide-induced flare in high-grade gliomas: a new clinical entity
    M A Rosenthal
    Department of Medical Oncology and Clinical Haematology, Royal Melbourne Hospital, Parkville, Victoria, Australia
    Intern Med J 32:346-8. 2002
    ..We believe this represents the novel clinical entity of temozolomide-induced tumour flare...
  7. ncbi request reprint Staged autologous peripheral blood progenitor cell transplantation for Ewing sarcoma and rhabdomyosarcoma
    D S Ritchie
    Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
    Intern Med J 34:431-4. 2004
  8. doi request reprint Survival comparison between glioblastoma multiforme and other incurable cancers
    B Tran
    Department of Medical Oncology, Royal Melbourne Hospital, Grattan Street, Parkville, Victoria 3050, Australia
    J Clin Neurosci 17:417-21. 2010
    ..Our results demonstrate that with modern treatment, GBM survival is now comparable to, if not better than, many other incurable cancers...
  9. doi request reprint Imaging modalities in high-grade gliomas: pseudoprogression, recurrence, or necrosis?
    I Caroline
    Department of Medical Oncology, Royal Melbourne Hospital, Grattan Street, Parkville, Victoria 3050, Australia
    J Clin Neurosci 19:633-7. 2012
    ..However, further prospective studies comparing the clinical utility of MRI, PET, and SPECT are needed to establish the most reliable diagnostic tool for the differentiation of PP, RN and PD in HGG...
  10. ncbi request reprint Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia
    M A Rosenthal
    Department of Medical Oncology and Clinical Hematology, Royal Melbourne Hospital, Parkville, Victoria, Australia
    Ann Oncol 13:770-6. 2002
    ..Preclinical data demonstrates that PI-88 inhibits angiogenesis and has anti-metastatic effects. The aim of this phase I study was to determine the recommended dose and toxicity profile of PI-88...
  11. pmc Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer
    N M Corcoran
    Department of Surgery, Division of Urology University of Melbourne, Royal Melbourne Hospital, 5th Floor Clinical Sciences Building, Royal Parade, Parkville, Victoria 3050, Australia
    Br J Cancer 103:462-8. 2010
    ..Angiogenesis is fundamental to the progression of many solid tumours including prostate cancer. Sodium selenate is a small, water-soluble, orally bioavailable activator of PP2A phosphatase with anti-angiogenic properties...
  12. doi request reprint Local perspective on a rare brain tumour: adult medulloblastoma
    S F Wong
    Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
    Intern Med J 43:567-72. 2013
    ..It is unclear whether treatment, extrapolated from paediatric protocols despite known differences between the two groups, results in comparable efficacy...
  13. ncbi request reprint Management of brain metastases
    L C Lim
    Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
    Intern Med J 34:270-8. 2004
    ..However, controversies remain regarding post-surgery irradiation in the setting of a solitary metastasis and the role of palliative chemotherapy...
  14. ncbi request reprint Diagnosing cancer: changing patterns of care
    E Lim
    Department of Medical Oncology, Melbourne Comprehensive Cancer Centre, Melbourne, Victoria, Australia
    Intern Med J 37:124-6. 2007
    ..6 days, compared with a similar study 13 years ago. This emphasizes the changing role of the oncologist in current day multidisciplinary cancer care...